

### IN THE CLAIMS

The claims are as follows:

1-52. (Canceled)

53. (Previously Presented) An isolated nucleic acid that comprises a nucleotide sequence that is the complete complement of SEQ ID NO:1 or SEQ ID NO:2;

wherein said nucleic acid, when introduced into a cell line that expresses a polynucleotide comprising SEQ ID NO:1 or SEQ ID NO:2 or which encodes a peripheral-type benzodiazepine receptor protein having a mutant threonine residue at position 147 and a mutant arginine residue at position 162 and having residues 27 to 169 of SEQ ID NO:3, inhibits the expression of the polynucleotide.

54. (Previously Presented) The nucleic acid of claim 53, which has the complete complement of SEQ ID NO:1.

55. (Previously Presented) The nucleic acid of claim 53, which has the complete complement of SEQ ID NO:2.

56-57. (Canceled)

58. (Withdrawn) A method for inhibiting the proliferation of a malignant cell line that expresses the PBR gene, comprising introducing into said cell line *in vitro* the nucleic acid according to claim 53 in an amount effective to inhibit cell proliferation.

59. (Withdrawn) A method for inhibiting the proliferation of a malignant cell line that expresses the PBR gene, comprising introducing into said cell line *in vitro* the nucleic acid according to claim 54 in an amount effective to inhibit cell proliferation.

60. (Withdrawn) A method for inhibiting the proliferation of a malignant cell line that expresses the PBR gene, comprising introducing into said cell line *in vitro* the nucleic acid according to claim 55 in an amount effective to inhibit cell proliferation.

61-62. (Canceled)

63. (Previously Presented) The nucleic acid of claim 53, which is comprised in a proteoliposome containing viral envelope receptor proteins.

64. (Previously Presented) The nucleic acid of claim 53, which is present in a vector.

65. (Canceled)

66. (Previously Presented) The nucleic acid of claim 53, which is contained in a carrier.

67. (Previously Presented) The nucleic acid of claim 66 wherein said carrier is a protein selected from the group consisting of a cytokine or polylysine-glycoprotein carrier.

68. (Previously Presented) The nucleic acid of claim 53, which is comprised in a microbead.

69. (Canceled)

70. (Previously Presented) The nucleic acid of claim 53, which consists of the complete complement of SEQ ID NO:1 or SEQ ID NO:2.

71. (Canceled)

72. (Previously Presented) The nucleic acid of claim 64, which is synthesized in a mammalian cell *in vitro* following introduction of said vector into said cell.

73. (Previously Presented) The nucleic acid of claim 72, which is synthesized in an amount effective to inhibit expression of the polynucleotide comprising SEQ ID NO:1 or SEQ ID NO:2 or which encodes a peripheral-type benzodiazepine receptor protein having a mutant threonine residue at position 147 and a mutant arginine residue at position 162 and having residues 27 to 169 of SEQ ID NO:3 in the cell line.

74. (Previously Presented) A composition comprising the isolated nucleic acid of claim 53, 81 or 82.

75-77. (Canceled)

78. (Previously Presented) The composition of claim 74, wherein the nucleic acid is present in a vector and is synthesized in a mammalian cell *in vitro* following introduction of said vector into said cell.

79. (Previously Presented) The composition of claim 78, wherein the nucleic acid is synthesized in a mammary gland cell *in vitro* following introduction of said vector into said mammary gland cell.

80. (Canceled)

81. (Previously Presented) An isolated nucleic acid consisting of SEQ ID NO:1, SEQ ID NO:2, or the complete complement thereof.

82. (Previously Presented) An isolated nucleic acid encoding a peripheral benzodiazepine receptor protein having residues 27 to 169 of SEQ ID NO:3.